Across TCGA pan-cancer cohorts, ATG4D mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of ATG4D’s most consistent transcriptional readouts.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ATG4D mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ATG4D is over-expressed in tumor.
LSCC and HNSC are the cancer types where ATG4D tumor–normal differential expression is most reproducible.